ArticleCancers2026
Stem Cell Mobilization and Autologous Transplantation Outcomes After First-Line R-DA-EPOCH in High-Risk DLBCL and HGBCL: A Single-Center Retrospective Study.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesPatients with high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBCL) have suboptimal outcomes with standard therapies. Dose-adjusted R-EPOCH (R-DA-EPOCH) is often used in selected high-risk settings and may also serve as an effective chemo-mobilizing strategy for autologous stem cell transplantation (ASCT). We aimed to evaluate the impact of first-line R-DA-EPOCH on stem cell mobilization and transplantation outcomes.
methodsWe retrospectively analyzed 41 consecutive adult patients with high-risk DLBCL/HGBCL treated with first-line R-DA-EPOCH between 2016 and 2021. Stem cell collection was planned after cycle 5. The primary endpoint was the rate of poor mobilizers, defined as patients who collected <2 × 10
resultsThe rate of poor mobilizers was 31.7% (13/41), with 22% (9/41) of patients requiring PLX. Overall, 68% of patients achieved ≥2 × 10
conclusionsFirst-line R-DA-EPOCH enables effective stem cell mobilization in most high-risk DLBCL and HGBCL patients, although a substantial proportion require PLX support. These findings suggest that R-DA-EPOCH is a feasible platform for early mobilization and ASCT in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.